49,632 Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Bought by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC acquired a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 49,632 shares of the company’s stock, valued at approximately $1,708,000. New Age Alpha Advisors LLC owned 0.09% of Harmony Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after acquiring an additional 436 shares in the last quarter. Mendota Financial Group LLC lifted its stake in Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after purchasing an additional 965 shares during the last quarter. KBC Group NV boosted its position in Harmony Biosciences by 79.9% during the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after buying an additional 819 shares during the period. Quantbot Technologies LP bought a new position in shares of Harmony Biosciences during the third quarter valued at about $74,000. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock worth $80,000 after buying an additional 519 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, CFO Sandip Kapadia sold 1,775 shares of Harmony Biosciences stock in a transaction on Monday, January 27th. The stock was sold at an average price of $38.05, for a total transaction of $67,538.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeffrey Dierks sold 10,507 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total value of $388,864.07. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock valued at $2,831,679 in the last three months. Company insiders own 30.80% of the company’s stock.

Harmony Biosciences Stock Performance

Shares of HRMY opened at $33.19 on Monday. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The company has a 50-day simple moving average of $36.01 and a two-hundred day simple moving average of $35.47. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The firm has a market capitalization of $1.90 billion, a PE ratio of 15.73, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.11. The company had revenue of $201.30 million for the quarter, compared to analysts’ expectations of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.45 earnings per share. On average, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on HRMY shares. Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a “buy” rating and a $55.00 price target on the stock. HC Wainwright cut their target price on shares of Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Mizuho upped their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a report on Tuesday, March 18th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a report on Tuesday, February 25th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $53.33.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.